Bank Julius Baer & Co. Ltd Zurich lowered its position in Catalent, Inc. (NYSE:CTLT – Get Rating) by 16.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,562 shares of the company's stock after selling 3,960 shares during the period. Bank Julius Baer & Co. Ltd Zurich's holdings in Catalent were worth $1,488,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also recently bought and sold shares of the company. Tokio Marine Asset Management Co. Ltd. boosted its position in Catalent by 22.5% in the second quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,043 shares of the company's stock valued at $326,000 after buying an additional 558 shares during the last quarter. US Bancorp DE boosted its position in Catalent by 1.4% in the 3rd quarter. US Bancorp DE now owns 19,237 shares of the company's stock worth $1,392,000 after purchasing an additional 272 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp boosted its position in Catalent by 12.0% in the 2nd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 90,954 shares of the company's stock worth $9,759,000 after purchasing an additional 9,723 shares in the last quarter. Illinois Municipal Retirement Fund boosted its position in Catalent by 88.1% in the 2nd quarter. Illinois Municipal Retirement Fund now owns 6,028 shares of the company's stock worth $647,000 after purchasing an additional 2,824 shares in the last quarter. Finally, Private Advisor Group LLC boosted its position in Catalent by 98.5% in the 2nd quarter. Private Advisor Group LLC now owns 5,870 shares of the company's stock worth $630,000 after purchasing an additional 2,913 shares in the last quarter. Hedge funds and other institutional investors own 99.38% of the company's stock.
Get Catalent alerts:Catalent Stock Performance
Shares of Catalent stock opened at $49.57 on Wednesday. The business has a 50-day moving average of $46.22 and a 200 day moving average of $72.04. Catalent, Inc. has a 12 month low of $40.69 and a 12 month high of $115.33. The stock has a market capitalization of $8.92 billion, a price-to-earnings ratio of 21.18, a price-to-earnings-growth ratio of 3.63 and a beta of 1.24. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.86 and a quick ratio of 2.08.
Catalent (NYSE:CTLT – Get Rating) last announced its earnings results on Tuesday, November 1st. The company reported $0.25 EPS for the quarter, missing analysts' consensus estimates of $0.49 by ($0.24). Catalent had a net margin of 8.83% and a return on equity of 12.55%. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.06 billion. As a group, sell-side analysts forecast that Catalent, Inc. will post 2.93 earnings per share for the current year.Insider Buying and Selling at Catalent
In other Catalent news, SVP Michael J. Grippo sold 2,451 shares of the stock in a transaction dated Monday, October 31st. The stock was sold at an average price of $65.83, for a total value of $161,349.33. Following the sale, the senior vice president now owns 17,792 shares of the company's stock, valued at approximately $1,171,247.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Michael J. Grippo sold 2,451 shares of the firm's stock in a transaction dated Monday, October 31st. The stock was sold at an average price of $65.83, for a total transaction of $161,349.33. Following the sale, the senior vice president now owns 17,792 shares of the company's stock, valued at approximately $1,171,247.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Manja Boerman sold 780 shares of the firm's stock in a transaction dated Monday, December 5th. The stock was sold at an average price of $51.70, for a total value of $40,326.00. Following the sale, the insider now directly owns 15,860 shares in the company, valued at approximately $819,962. The disclosure for this sale can be found here. 0.58% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Several equities research analysts have commented on CTLT shares. Barclays lowered their price objective on Catalent from $62.00 to $58.00 and set an "overweight" rating on the stock in a research report on Tuesday. KeyCorp reduced their target price on Catalent from $125.00 to $85.00 and set an "overweight" rating for the company in a research note on Wednesday, November 2nd. TheStreet downgraded Catalent from a "b-" rating to a "c+" rating in a research note on Friday, October 28th. Argus downgraded Catalent from a "buy" rating to a "hold" rating in a research note on Monday, November 7th. Finally, Robert W. Baird reduced their price objective on Catalent from $123.00 to $75.00 in a research note on Wednesday, November 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $92.40.
About Catalent
(Get Rating)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Featured Articles
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.